ENDRA Life Sciences (NDRA) Cost of Revenue (2016 - 2026)

ENDRA Life Sciences has disclosed Cost of Revenue across 11 years of filings, most recently posting $4278.0 for Q1 2026.

• In Q1 2026, Cost of Revenue fell 93.8% year-over-year to $4278.0; the TTM figure through Mar 2026 stood at $124757.0 (down 68.92% YoY), while the FY2025 annual figure was $189470.0, down 66.82% from the prior year.
• Cost of Revenue retreated to $4278.0 in Q1 2026, from $6360.0 in the prior quarter.
• Over the last five years, Cost of Revenue for NDRA reached as high as $420439.0 in Q3 2022 and fell as low as $4278.0 in Q1 2026.
• The 5-year median for Cost of Revenue is $162952.0 (2024), against an average of $177323.1.
• Annual changes were most pronounced in 2022 — Cost of Revenue jumped 111.21% — and 2026, when it sank 93.8%.
• A 5-year view of Cost of Revenue shows it stood at $326769.0 in 2022, then slumped by 54.76% to $147833.0 in 2023, then sank by 41.64% to $86271.0 in 2024, then plunged by 92.63% to $6360.0 in 2025, then plunged by 32.74% to $4278.0 in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $4278.0, $6360.0, and $45285.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.